

Treat-to-target and Improving Outcomes in Psoriasis: A Report from the GRAPPA 2014 Annual Meeting

Junko Takeshita, April W. Armstrong, Philip J. Mease, and Joel M. Gelfand

ABSTRACT. Treat-to-target strategies are part of routine clinical practice in cardiovascular medicine. This approach, however, is relatively new in rheumatology and dermatology and has not been widely applied to the management of psoriatic diseases. At the 2014 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) in New York, New York, USA, several GRAPPA members summarized and participated in a panel discussion on the treat-to-target concept as it applies to psoriasis, its potential role in improving treatment outcomes, identification of specific treatment targets for psoriasis, and future directions for research. (J Rheumatol 2015;42:1037–40; doi:10.3899/jrheum.150128)

Key Indexing Terms:

PSORIASIS

PSORIATIC ARTHRITIS

TREAT-TO-TARGET

OUTCOMES

At the 2014 GRAPPA Annual Meeting, the topic of treating to target and improving outcomes in psoriasis was addressed in an overview by Dr. Joel Gelfand, followed by a panel discussion with Drs. Gelfand, Philip Mease, and Junko Takeshita, and moderated by Dr. April Armstrong. Topics included treatment target options for psoriasis, timepoints for assessing those targets, and the importance of research to establish and support treat-to-target strategies for managing psoriasis. The audience was also polled for their opinions on treatment targets in psoriasis.

Treat-to-target: Definition, History, and Potential Role in the Management of Psoriatic Diseases

Dr. Gelfand summarized the concept of “treat-to-target” and discussed its potential applicability to psoriasis. Treat-to-target is not a new concept in medicine; the underlying principle is preventive therapy to improve patient outcomes by treating a disease until a prespecified objective measure is achieved. Treatment options generally have a strong evidence base with proven efficacy/effectiveness and safety data from

randomized controlled trials (RCT) or observational studies. Treat-to-target originated and has become a well-established practice in cardiovascular medicine. However, appropriate treatment targets remain a matter of debate and continue to evolve across all medical specialties. Although treatment to a specified target is meant to improve outcomes, focused attention on 1 target may result in oversight of unintended consequences. For example, while 2 clinical trials of patients with type 1¹ and type 2² diabetes showed stricter glycemic control to be associated with reductions in late diabetic microvascular complications, a subsequent clinical trial of type 2 diabetics found intensive glucose-lowering therapy to be also associated with increased mortality³. The 2013 American College of Cardiology/American Heart Association Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults recommendation to abandon previous cholesterol treatment targets in favor of fixed-dose cholesterol-lowering strategies⁴ exemplifies another treatment target controversy.

Treat-to-target strategies are also being adapted for rheumatoid arthritis based on clinical trials that showed reduction of disease activity with set treatment goals^{5,6,7,8}. However, treat-to-target strategies have not been well-studied in psoriatic diseases. In a single open-label RCT of intensive management versus standard care in the treatment of early psoriatic arthritis (PsA; Tight Control of PsA; TICOPA)⁹, preliminary analyses suggest that tight control of PsA is associated with improved joint outcomes. The tight-control group was more likely than the standard-care group to achieve American College of Rheumatology (ACR) 20 response at 48 weeks (OR 1.91; 95% CI, 1.03–3.55)¹⁰. However, adverse events were also more frequent among the tight-control group versus the standard-care group.

Unlike in the management of PsA, where treatment with tumor necrosis factor inhibitors is associated with reduction

From the Department of Dermatology and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA; Colorado Health Outcomes Program (COHO), University of Colorado Denver, Denver, Colorado, USA; and Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA.

J. Takeshita, MD, PhD, Department of Dermatology and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine; A.W. Armstrong, MD, MPH, COHO, University of Colorado Denver; P.J. Mease, MD, Swedish Medical Center and University of Washington School of Medicine; J.M. Gelfand, MD, MSCE, Department of Dermatology and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine.

Address correspondence to Dr. J. Takeshita, Department of Dermatology and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, University of Pennsylvania, One Convention Ave., 1463 Penn Tower, Philadelphia, Pennsylvania 19104, USA. E-mail: Junko.Takeshita@uphs.upenn.edu

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2015. All rights reserved.

in radiographic progression of disease¹¹, the panelists noted that the benefits of psoriasis treatment, beyond objective improvement of skin disease, remain to be shown empirically. Particularly among patients with moderate to severe disease who are at increased risk of developing major adverse cardiovascular events^{12,13,14,15}, diabetes¹⁶, and chronic kidney disease¹⁷, culminating in an average 5-year shorter lifespan than patients without psoriasis, psoriasis therapies may provide benefits beyond the skin. The potential systemic benefits of psoriasis therapies have been suggested in some^{18,19,20} but not all^{21,22} observational studies, and experimental studies have yet to be completed. Thus, further research is required to definitively support and establish the benefits of treatment targets in psoriasis.

Target Endpoints: Disease Activity and Other Targets

Disease activity targets rely on measures that capture psoriasis severity. Several such measures exist^{23,24}, but each has important limitations to consider. The panelists discussed characteristics of ideal disease activity measures, including ready incorporation into the clinical setting (i.e., easy and quick measurements), accountability for both overall extent of involvement and the component characteristics of psoriatic lesions, applicability to different psoriasis types, and utility as both a single static measure and a measure of change over time.

Primary clinical trial efficacy endpoints have traditionally included the Psoriasis Area and Severity Index (PASI)⁷⁵, defined by $\geq 75\%$ improvement in PASI score; and physician's global assessment (PGA)-defined clear or almost clear skin, typically corresponding to scores of $\leq 1^{25}$. With the development of increasingly efficacious therapies, PASI90 and 100 are also being reported^{26,27}. In the real-world clinical setting, however, treatment endpoints remain poorly defined. Guidelines with suggested treatment goals have been established in Canada²⁸, Europe^{29,30}, the United Kingdom³¹, and Australia²¹ and are largely based on expert opinion. Most recommendations identify PASI75 as a primary treatment goal despite the PASI score being time-consuming and cumbersome to calculate and having little significance as a single score. Less intensive assessments — used more readily in the clinic — are percent body surface area (BSA) of psoriasis involvement and PGA; however, each measure has its limitations. BSA involvement does not assess the severity of individual psoriatic lesions (i.e., extent of erythema, induration, and scale); whereas PGA does not incorporate BSA involved by psoriasis. These limitations may be overcome by using the product of BSA and PGA [Simple-Measure for Assessing Psoriasis Activity (BSA \times PGA)], which has been highly correlated to PASI scores in initial studies^{31a} and may be a promising disease activity measure in the clinical setting. The PASI, BSA, and PGA scores are further limited by their inability to adequately capture disease activity for non-plaque types of psoriasis.

Thus, the panelists emphasized the need to develop additional disease activity measures for other psoriasis types (e.g., the Brigham Scalp Nail Inverse Palmoplantar Psoriasis Composite Index; B-SNIPI)³².

With an increasing focus on patient-centered medicine³³ and the importance of including the patient perspective, the panelists also discussed patient-reported outcomes (PRO) as targets for improving psoriasis care. Many treatment guidelines^{29,30,31,34} also incorporate a patient-reported dermatology-specific health-related quality of life (QoL) measure, most commonly the Dermatology Life Quality Index (DLQI)^{35,36}, where suggested secondary treatment goals include ≥ 5 -point improvement in DLQI score³¹, $DLQI \leq 1^{29}$ (i.e., no effect of patient's skin disease on QoL), or $DLQI \leq 5^{30,37}$ (i.e., no effect to small effect on QoL). In general, objective data supporting the use of PRO or objective disease activity measures as targets in psoriasis are sparse. Few studies have evaluated the effect of low skin disease burden on patient-reported QoL. Secondary analyses of data from 2 phase III adalimumab RCT²⁷ found significantly greater improvement of DLQI and Medical Outcomes Study Short Form-36 (SF-36) scores among patients who achieved PASI90 and 100 versus patients with lower levels of PASI response. Similarly, secondary analyses from a phase II brodalumab RCT³⁷ showed significantly greater improvement of DLQI and Psoriasis Symptom Inventory (PSI) scores among patients who achieved PASI100 versus those who achieved PASI75 but not PASI100; additionally, patients who achieved complete skin clearance (PGA = 0) were more likely to report DLQI and PSI scores of zero (i.e., no effect of skin disease on QoL, and no psoriasis-related symptoms, respectively) versus patients with almost clear skin (PGA = 1). Further, in a clinic-based, multicenter, cross-sectional study of patients with moderate to severe psoriasis with clear or almost clear skin, 76% of patients with clear versus 44% with almost clear skin reported no effect of their skin disease on QoL (i.e., $DLQI \leq 1$). In fully adjusted analyses, patients with clear versus almost clear skin were 60% more likely to report no effect of their skin disease on QoL, independent of basic demographic and clinical factors, psoriasis history, and current therapy for psoriasis³⁸. Thus, complete skin clearance (PASI100 or PGA score of zero) is an important treatment target from the patient perspective. However, none of the aforementioned studies assessed the relative safety and cost effectiveness of such treatment strategies. Further studies are therefore necessary before implementing physician- or patient-reported treatment targets in routine practice.

Lastly, with multiple potential disease activity measures, PRO, and comorbidities, particularly PsA, the panelists discussed the need to consider multiple treatment targets (e.g., simultaneous disease activity and QoL targets or combined skin and joint disease targets) and to prioritize targets. For example, in a patient with both psoriasis and PsA,

should reaching joint disease targets supersede that of skin disease? Should objective disease activity or QoL be prioritized in managing patients with psoriatic diseases? It will be important to address these questions and to also elicit and incorporate patients' opinions regarding these and other issues, including acceptable risk-benefit ratios and assessment frequency, as treat-to-target strategies for psoriasis are established.

Time to Treatment Targets

Two treatment phases should be considered when assessing treatment targets: induction and maintenance. The induction phase is the time from initiation of therapy to maximal response; maintenance is the time period after induction. Assessment timepoints may vary depending on the treatment phase. Historically, clinical trials assess efficacy at 12 weeks after therapy initiation — the time at which the majority of patients reach maximal response to most moderate to severe psoriasis therapies. In the absence of large-scale RCT to guide the identification of optimal outcome assessment frequency, existing guidelines suggest assessing initial response up to 16 weeks after initiation of therapy or up to 24 weeks for therapies with slower onset of action^{29,30}. Ideal assessment frequency during maintenance is even less clear, with guidelines suggesting routine followup as directed by the specific therapy, which may be as frequent as 2 months for systemic medications³⁰.

Audience Responses to Psoriasis Treatment Target and Priorities Questions

Following the presentation and panel discussion, audience members were polled for their answers to 6 questions with instructions to choose a single best response. Questions and answers are summarized in Table 1.

The majority of respondents were PsA researchers or healthcare providers. The majority chose disease activity targets that reflected complete skin clearance or minimal disease activity, and PRO targets that reflected no effect of skin disease on QoL. Prioritization of treatment targets favored PsA over psoriasis, reflecting the identification of the majority as PsA researchers or healthcare providers. Further, most deemed QoL to be more important than psoriasis or PsA disease activity as treatment targets, emphasizing the ongoing trend of increasing incorporation of PRO in the practice of medicine. Importantly, stratification of responses by respondent category revealed that patients or patient advocates had strong preferences for skin clearance (i.e., PASI100, PGA = 0) as treatment targets, with all prioritizing QoL targets over objective disease activity targets.

Treat-to-target strategies are increasingly being incorporated into management of chronic diseases. Further studies are necessary to establish the benefit of incorporating treat-to-target concepts into routine dermatologic practice.

Table 1. Audience responses to psoriasis treatment target and priorities questions. Responses are n (%).

1. What is your primary role? (Total responses N = 125)	
a. Psoriasis researcher/healthcare provider	28 (22)
b. PsA researcher/healthcare provider	88 (70)
c. Patient/patient advocate	9 (7)
2. What is an appropriate target regarding change in PASI? (N = 149)	
a. \geq PASI75	84 (56)
b. \geq PASI90	54 (36)
c. PASI100	11 (7)
3. What is an appropriate target regarding BSA? (N = 148)	
a. \leq 10%	11 (7)
b. \leq 5%	17 (11)
c. \leq 3%	48 (32)
d. \leq 1%	64 (43)
e. 0%	8 (5)
4. What is an appropriate target regarding PGA? (N = 152)	
a. At most mild (i.e., mild, almost clear, or clear)	16 (11)
b. At most almost clear (i.e., almost clear or clear)	99 (65)
c. Clear	37 (24)
5. What is an appropriate target regarding DLQI? (N = 135)	
a. \leq 5 (i.e., no to small effect on QoL)	24 (18)
b. \leq 1 (i.e., no effect on QoL)	93 (69)
c. 0 (i.e., no effect on QoL)	18 (13)
6. This is how I would prioritize "targets" in the treat-to-target approach (N = 137)	
a. Psoriasis disease activity > QoL > PsA disease activity	2 (1)
b. Psoriasis disease activity > PsA disease activity > QoL	8 (6)
c. QoL > psoriasis disease activity > PsA disease activity	21 (15)
d. QoL > PsA disease activity > psoriasis disease activity	62 (45)
e. PsA disease activity > psoriasis disease activity > QoL	23 (17)
f. PsA disease activity > QoL > psoriasis disease activity	21 (15)

PsA: psoriatic arthritis; PASI: Psoriasis Area and Severity Index; BSA: body surface area; QoL: quality of life; DLQI: Dermatology Life Quality Index; PGA: physician's global assessment.

REFERENCES

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. *N Engl J Med* 1993;329:977-86.
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998;352:837-53.
3. Gerstein HC, Miller ME, Byington RP, Goff DC Jr., Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 2008;358:2545-59.
4. Smith SC Jr., Grundy SM. 2013 ACC/AHA guideline recommends fixed-dose strategies instead of targeted goals to lower blood cholesterol. *J Am Coll Cardiol* 2014;64:601-12.
5. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Kerstens PJ, Nielen MM, Vos K, van Schaardenburg D, et al. DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. *Ann Rheum Dis* 2010;69:65-9.
6. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. *Lancet* 2004;364:263-9.
7. Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted

- Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). *Ann Rheum Dis* 2007;66:1443-9.
8. Rantalaaho V, Korpela M, Hannonen P, Kautiainen H, Jarvenpaa S, Leirisalo-Repo M, et al. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial. *Arthritis Rheum* 2009;60:1222-31.
 9. Coates LC, Navarro-Coy N, Brown SR, Brown S, McParland L, Collier H, et al. The TICOPA protocol (Tight Control of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. *BMC Musculoskelet Disord* 2013;14:101.
 10. Coates LC, Moverley A, McParland L, Brown S, Collier H, Brown SR, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a multicentre, open-label, randomised controlled trial [abstract]. *Lancet* 2014;383:S36.
 11. Gladman DD. Early psoriatic arthritis. *Rheum Dis Clin North Am* 2012;38:373-86.
 12. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. *JAMA* 2006;296:1735-41.
 13. Gelfand JM, Dommasch ED, Shin DB, Azfar RS, Kurd SK, Wang X, et al. The risk of stroke in patients with psoriasis. *J Invest Dermatol* 2009;129:2411-8.
 14. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. *Eur Heart J* 2010;31:1000-6.
 15. Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. *J Am Heart Assoc* 2013;2:e000062.
 16. Azfar RS, Seminara NM, Shin DB, Troxel AB, Margolis DJ, Gelfand JM. Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis. *Arch Dermatol* 2012;148:995-1000.
 17. Wan J, Wang S, Haynes K, Denburg MR, Shin DB, Gelfand JM. Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study. *BMJ* 2013;347:f5961.
 18. Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. *J Am Acad Dermatol* 2005;52:262-7.
 19. Wu JJ, Poon KY, Channul JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. *Arch Dermatol* 2012;148:1244-50.
 20. Ahlehoof O, Skov L, Gislasen G, Lindhardsen J, Kristensen SL, Iversen L, et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. *J Intern Med* 2013;273:197-204.
 21. Chen YJ, Chang YT, Shen JL, Chen TT, Wang CB, Chen CM, et al. Association between systemic antipsoriatic drugs and cardiovascular risk in patients with psoriasis with or without psoriatic arthritis: a nationwide cohort study. *Arthritis Rheum* 2012;64:1879-87.
 22. Abuabara K, Lee H, Kimball AB. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. *Br J Dermatol* 2011;165:1066-73.
 23. Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. *J Invest Dermatol* 2010;130:933-43.
 24. Chalmers RJ. Assessing psoriasis severity and outcomes for clinical trials and routine clinical practice. *Dermatol Clin* 2015;33:57-71.
 25. Robinson A, Kardos M, Kimball AB. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. *J Am Acad Dermatol* 2012;66:369-75.
 26. Torii H, Sato N, Yoshinari T, Nakagawa H, Japanese Infliximab Study I. Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab. *J Dermatol* 2012;39:253-9.
 27. Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. *Dermatology* 2008;216:260-70.
 28. Canadian Psoriasis Guidelines Committee. Canadian guidelines for the management of plaque psoriasis. Updated 2009. [Internet. Accessed March 12, 2015.] Available from: www.dermatology.ca/wp-content/uploads/2012/01/cdnpsoriasisguidelines.pdf
 29. Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. *J Eur Acad Dermatol Venereol* 2009;23 Suppl 2:1-70.
 30. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. *Arch Dermatol Res* 2011;303:1-10.
 31. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler DA, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. *Br J Dermatol* 2009;161:987-1019.
 - 31.a. Walsh JA, McFadden M, Woodcock J, Clegg DO, Helliwell P, Dommasch E, et al. Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. *J Am Acad Dermatol* 2013;69:931-7.
 32. Patel M, Liu SW, Qureshi A, Merola JF. The Brigham Scalp Nail Inverse Palmoplantar Psoriasis Composite Index (B-SNIPI): a novel index to measure all non-plaque psoriasis subsets. *J Rheumatol* 2014;41:1230-2.
 33. Laine C, Davidoff F. Patient-centered medicine. A professional evolution. *JAMA* 1996;275:152-6.
 34. Baker C, Mack A, Cooper A, Fischer G, Shumack S, Sidhu S, et al. Treatment goals for moderate to severe psoriasis: an Australian consensus. *Australas J Dermatol* 2013;54:148-54.
 35. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. *Clin Exp Dermatol* 1994;19:210-6.
 36. Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CE. Quality of life measures in psoriasis: a critical appraisal of their quality. *J Clin Pharm Ther* 1998;23:391-8.
 37. Viswanathan HN, Chau D, Milmont CE, Yang W, Erond N, Revicki DA, et al. Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis. *J Dermatolog Treat* 2014 Jul 31 (E-pub ahead of print).
 38. Takeshita J, Callis Duffin K, Shin DB, Krueger GG, Robertson AD, Troxel AB, et al. Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting. *J Am Acad Dermatol* 2014;71:633-41.